ESMO TAT 2023 | Identifying neoantigen-specific T cells to increase the immunogenic response to TIL therapy

Elena Garralda Cabanas, MD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, discusses her research in selecting immunogenic neoantigen-specific tumor infiltrating lymphocytes (TILs) for patients with melanoma. In TIL therapy, TILs are isolated from tumors and expanded in a laboratory before being infused back to the patient where they selectively attack cancer cells. Dr Garralda Cabanas explains that patients with high numbers of neoantigen-specific TILs in tumors are found to respond better to this immunotherapy and poses that enrichment of TILs with neoantigen-specific T cells could increase the number of patients that respond, with fewer immunogenic tumors. Dr Garrala Cabanas also discusses her work on isolating TILs from biopsies, rather than resected tumors. Once a neoantigen specific T cells has been identified, commonly expressed neoantigens selected by sequencing techniques will be expressed on B cells and cross-reacted with TILs to identify the reactive cells that are given to the patient. This interview took place at the ESMO Targeted Anticancer Therapies (TAT) Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.